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1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory 
disease, which, if treated inadequately, leads to irreversible 
joint damage, resulting in deformities, disability and 
premature mortality. The disease occurs worldwide and 
affects approximately 1% of the population.[1,2]
Recently, there have been major developments in the management 
of RA. These include (i) advances in the early diagnosis of the disease 
and evidence for the benefit of early therapy; (ii) better tools to assess 
response to therapy with the development of composite disease 
activity scores, allowing goal-directed therapy where the target is 
remission; and (iii) the emergence of biologic disease-modifying 
anti-rheumatic drugs (DMARDs). These strategies result in better 
control of inflammation, thus preventing joint damage and reducing 
disability. Against this background, the South African Rheumatism 
and Arthritis Association (SARAA) has proposed the development 
of an updated treatment strategy for the effective therapy of RA in 
South Africa (SA). These recommendations are aimed at all healthcare 
professionals managing RA, including rheumatologists, physicians, 
general practitioners, nurses and allied healthcare professionals. 
SARAA adhered to the following ideologies when formulating these 
recommendations:
• They should be aimed at all healthcare professionals managing RA, 
including allied healthcare professionals, nurses, general practitioners, 
physicians and rheumatologists.
• There should be consultation with pivotal stakeholders in the final 
consensus of the document. 
• They should be based on scientific evidence or, if unavailable, expert 
consensus. 
• They should be recommendations and not a guideline. Management 
of RA is not cast in stone (and is likely to change again in the near 
future) and failure to adhere to them is not incriminating or negligent. 
They represent what SARAA, as a professional body, recommends and 
set a certain standard of care that should be aimed for, from the very 
basic management to the highly sophisticated. Should practitioners 
not be able to offer expertise where appropriate, they may consider 
referral to a centre that does. 
• There are limitations to all recommendations and they cannot cover 
all clinical problems, but should be detailed enough to cover common 
circumstances, yet concise enough to be practical to the reader. 
• SA is a multi-faceted society and thus a ‘one size fits all’ policy is not 
rational for all practitioners and patients, but these recommendations 
should be insightful to treating practitioners and stakeholders. 
• These recommendations should be disseminated widely. 
2. Scope
The treatment strategy is presented in the form of an algorithm (Fig. 1), 
and is accompanied by a more in-depth discussion of key management 
principles. This algorithm provides a step-wise approach to treatment, 
to enable health authorities and practitioners to develop and support the 
most effective method of achieving and maintaining remission in RA 
patients in both public and private health sectors. The purpose is not to 
remove the physician’s autonomy, and physicians must select the most 
appropriate therapeutic option, taking into consideration the patient’s 
preferences.
3. Methods
For this guideline to be widely accepted, the following methodology 
has been followed. Evidence from the literature and from RA guidelines 
developed elsewhere in the world has been reviewed. An online survey 
sent to all SA rheumatologists was performed to assess the level of 
agreement with key points relating to RA therapy. Various stakeholders 
including the Department of Health, medical funders, the Registrar 
of Medical Schemes, patient representative bodies (i.e. the Arthritis 
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Foundation) and academic departments have 
been consulted. 
4. Key principles
4.1 Early diagnosis and treatment
Untreated RA results in severe disability 
and loss of health-related quality of life. [3] 
There is a direct relationship between the 
duration of uncontrolled inflammation 
and joint damage (as measured by bony 
erosions and joint space narrowing).[4] Joint 
damage begins within the first 3 - 6 months 
after disease onset and a narrow window of 
opportunity exists where early aggressive 
therapy of RA can suppress inflammation 
before irreversible joint destruction has 
occurred.[5-7] Thus, early diagnosis and 
prompt referral to a physician, or ideally to 
a rheumatologist, for initiation of DMARDs 
is critical. To this end, the American 
College of Rheumatology (ACR)/European 
League Against Rheumatism (EULAR) 
have developed updated criteria for the 
classification of RA (Table 1).[8] These new 
criteria may enable practitioners to make 
a much earlier diagnosis of RA than the 
previous ACR criteria.[9] Screening tools, 
such as the ‘S-factor’ developed by Arthritis 
Research UK and the Gait, Arms, Legs, and 
Spine (GALS) examination, may support 
primary healthcare workers in diagnosing 
inflammatory arthritis, promoting timeous 
referrals to specialists to initiate DMARDs 
(Table 2).[10,11] 
4.2 Assessment
4.2.1 Disease activity 
There have been significant advances in the 
methods of scoring disease activity in RA, 
where the clinical examination of tender 
and swollen joints, global assessments and 
laboratory investigations are combined in 
a composite disease activity score. The 3 
validated scores currently in use in SA are the 
28-Joint Disease Activity Score (DAS-28), the 
Simplified Disease Activity Index (SDAI), and 
the Clinical Disease Activity Index (CDAI) 
(Table 3).[12-14] These scores allow classification 
of the patient into a state of remission or low, 
moderate or high disease activity, providing 
a simple tool for assessing disease at each 
patient visit to guide therapeutic decisions.[15] 
The results of clinical trials are expressed 
according to the percentage of patients 
achieving an ACR  20, ACR  50 or ACR  70 
response. An ACR 20 response is defined by a 
≥20% improvement in tender and swollen joint 
counts, and in 3 of the remaining 5 criteria.[16] 
The ACR  50 and ACR  70 represent a 50% 
or 70% improvement in these parameters, 
respectively. In general, the proportion of 
patients achieving an ACR  20 is higher than 
those achieving an ACR 50 or ACR 70. 
4.2.2 Goal-directed therapy 
In other fields of medicine, treatment targets 
have been defined and treatment aimed at 
achieving these targets has led to improved 
outcomes with less end-organ damage. 
Examples include HbA1c level in diabetes 
mellitus, blood pressure measurement in 
hypertension, and cholesterol level in dys-
lipidaemia. In RA, there is evidence that 
obtaining tight control of disease activity, 
with a pre-defined goal of low disease activity 
(LDA), or ideally, remission, to drive disease 
management decisions, allows better control of 
disease than routine clinic care. This intensive 
control strategy results in lower disease activity, 
better physical function and less structural 
damage, particularly when commenced in 
early disease.[17] For this reason, RA patients 
commenced on therapy may require evaluation 
as frequently as monthly, with calculation of a 
composite disease activity score at each visit, 
and escalation of DMARD therapy, until LDA 
(SDAI ≤11) or ideally remission (SDAI ≤3.3) 
is achieved, after which time, less frequent 
assessments (3 - 6-monthly) are acceptable. 
The target of LDA or remission should be 
maintained as long as possible, keeping in 
mind the individual patient’s risk for drug-
related complications or comorbid diseases.
4.2.3 Disability
Physical disability, with its negative conse-
quences on personal care, employment and 












































































Fig. 1. Algorithm for management of rheumatoid arthritis in SA. DMARD = disease-modifying anti-
rheumatic drug; LDA = low disease activity (SDAI ≤11); CXR = chest X-ray; TB = tuberculosis; LTBI = latent 
TB infection; TST = tuberculin skin test; IGRA = IFN-γ release assay. * Biologic therapy should be considered 
in patients with high disease activity, or moderate disease activity in the presence of poor prognostic factor/s 
(seropositivity, early radiographic erosions, extra-articular disease or functional disability). 
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social life, can be measured with a self-administered questionnaire, 
the Health Assessment Questionnaire - Disability Index (HAQ-DI). [18] 
In early disease, the HAQ-DI reflects joint inflammation and shows 
good correlation with clinical disease activity.[19] In established RA, 
physical function worsens annually as a consequence of irreversible 
joint damage.[20] The score ranges from 0 (no disability) to 3 (severe 
disability).
4.2.4 Radiography
Baseline radiographs of hands and feet should be performed for 
diagnostic and prognostic purposes. Erosions seen within the first 2 
years of disease are markers of aggressive disease,[21] but normal X-rays 
do not exclude the diagnosis of RA. In addition, a chest X-ray (CXR) 
is appropriate to assess rheumatoid lung involvement, to exclude 
tuberculosis (TB) prior to commencing DMARDs and to provide a 
baseline in the event of pulmonary complications of therapy. 
4.2.5 Sonar and MRI
Newer imaging modalities such as high-resolution ultrasound and 
magnetic resonance imaging (MRI) of peripheral joints allow detection 
of synovitis, joint space narrowing and erosions much earlier than 
is possible with conventional radiography.[22] Precise visualisation of 
anatomical structures allows more accurate diagnosis of joint and soft 
tissue pathology in the RA patient, and facilitates accurate placement 
of intra-articular injections, but these are not yet part of routine patient 
management.[23]
5. Therapy
5.1 Synthetic DMARDs 
Methotrexate (MTX) is the most widely prescribed DMARD, and is 
recommended as first-line therapy in doses starting at 7.5 - 15 mg 
weekly, with rapid dose escalation according to response and tolerability 
to a maximum of 25  mg weekly. The drug has an excellent safety 
profile, and although mild elevation of liver enzymes is not infrequent, 
this is usually transient, and cirrhosis is rare.[24,25] There is no evidence 
that higher doses are more effective, and they may increase toxicity. 
Antimalarials (chloroquine (CQ) or hydroxychloroquine, which is not 
currently available in SA), may be used as monotherapy for mild RA, or 
in combination with MTX for moderate to severe disease. Sulphasalazine 
(SSZ) is effective as monotherapy, and is particularly useful in patients 
in whom MTX is contraindicated, or as part of combination DMARD 
therapy. Similarly, leflunomide may be prescribed as monotherapy or 
co-prescribed with MTX. A summary of the doses, major side-effects 
and recommendations for monitoring patients is presented in Table 4, 
and further details have been given in previous SA guidelines for RA.[26] 
Patients who have failed MTX monotherapy should be treated with 
combination synthetic DMARDs. The most commonly prescribed 
combination treatment is MTX, SSZ and CQ. 
5.2 Glucocorticoids 
Glucocorticoids (GCs) rapidly reduce symptoms of RA and may 
inhibit development of erosions, particularly in early RA when used 
in combination with DMARDs.[27] However, side-effects limit their 
Table 1. 2010 ACR/EULAR RA Classification Criteria*
Criteria Score† 
A. Joints
1 large joint 0
2 - 10 large joints‡ 1
1 - 3 small joints§ 2
4 - 10 small joints 3
>10 joints 5
B. Serology
Negative RF and negative anti-CCP 0
Low-positive RF or low-positive ACPA¶ 2
High-positive RF or high-positive ACPA|| 3
C. Acute phase reactants
Normal CRP and ESR 0




ACR = American College of Rheumatology; EULAR = European League Against 
Rheumatism; RA = rheumatoid arthritis; RF = rheumatoid factor; CCP = cyclic 
citrullinated peptide; ACPA = anti-citrullinated peptide antibody; CRP = C-reactive 
protein; ESR = erythrocyte sedimentation rate. 
*Patients who (i) have at least 1 joint with definite synovitis (swelling), (ii) with the 
synovitis not better explained by another disease.
†Add score of categories A - D; a score of ≥6/10 is needed for classification of a patient as 
having definite RA.
‡‘Large joints’ refers to shoulders, elbows, hips, knees, and ankles.
§‘Small joints’ refers to the metacarpophalangeal joints, proximal interphalangeal joints, 
second through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists.
¶≤3 times the upper limit of normal.
||>3 times the upper limit of normal.
Table 2. ‘S-factors’ screening for early inflammatory arthritis 
(from Arthritis Care[10])*
Stiffness Early morning stiffness lasting >30 min
Swelling Persistent swelling of ≥1 joint, particularly 
hand joints
MCP squeeze test Tenderness on squeezing across all 4 MCP 
joints
MTP squeeze test Tenderness on squeezing across the 
metatarsal heads
MCP = metacarpophalangeal; MTP = metatarsophalangeal.
*Referral to a rheumatologist is recommended if ≥1 factor is present.




SDAI ≤3.3 ≤11 ≤26 >26 
CDAI ≤2.8 ≤10 ≤22 >22
DAS-28 ≤2.6 ≤3.2 ≤5.1 >5.1 
SDAI = Simplified Disease Activity Index; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment; MDGA = physician global assessment; CRP = C-reactive 
protein; CDAI = Clinical Disease Activity Index; DAS-28 = 28-Joint Disease Activity Score; ESR = erythrocyte sedimentation rate.
TJC + SJC + PGA (cm) + DGA (cm) + CRP (mg/dl)
TJC + SJC + PGA (cm) + DGA (cm)
0.56 * √TJC + 0.28 * √SJC + 0.7 * ln(ESR) + 0.014 * PGA (mm) 
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long-term use, and GCs are not appropriate as monotherapy. Low-
dose oral prednisone (≤10  mg/day) is appropriate in combination 
with DMARDs in early RA (<2 year disease duration) for up to 
6 months, after which the symptomatic effects seem to wane. 
In established RA, they may be used as ‘bridging’ therapy when 
DMARDs are initiated, and should be withdrawn once DMARDs 
have controlled the disease.[28,29] Intra-articular GCs are useful for a 
mono- or oligo-articular flare of disease. Long-acting intramuscular 
methylprednisolone may be used as an alternative to oral prednisone. 
5.3 Biologic DMARDs 
One of the most significant advances in the treatment of RA in 
recent years has been the development of biologic DMARDs, 
which are proteins directed against specific cytokines or their cell 
receptors. A wide choice of biologic DMARDs is now available in 
SA, with excellent efficacy in controlling RA in patients who have 
failed synthetic DMARD therapy. Clinical trials and post-marketing 
experience have shown that these DMARDs treat many aspects 
of RA disease: suppression of joint inflammation, prevention of 
radiographic progression, and improvement of physical function 
and health-related quality of life.[30] They may be classified into 
those inhibiting tumour necrosis factor (TNF) (i.e anti-TNF), and 
those targeting other cytokines or cells (non-anti-TNF). The ACR, 
EULAR and SARAA have developed recommendations for the use 
of these agents.[26,31,32] Biologic DMARDs are usually co-prescribed 
with MTX to improve efficacy and reduce antichimeric antibody 
production. The use of combination biologic DMARDs is not 
recommended. Table 5 summarises the biologics currently available, 
and provides details of dose and administration. Biologic DMARDs 
should be initiated by a rheumatologist, and information about 
patients on biologic therapy entered into a SARAA biologics 
registry.
5.4 Timing and choice of biologic therapy
In SA, commencement of biologic therapy after a 6-month trial of at 
least 3 synthetic DMARDs (including MTX, unless contraindicated) 
seems reasonable, given resource constraints, and given that up to 
one-third of patients will achieve LDA on synthetic DMARD 
therapy.[33,34] Indications for biologic therapy include an inadequate 
response to synthetic DMARD therapy, with high disease activity 
(SDAI >26), or moderate disease activity (SDAI 11 - 26) in the 
presence of poor prognostic factors (seropositivity, radiographic 
erosions within the first two years, extra-articular complications 
or functional disability). The efficacy of all currently available 
biologic drugs has been confirmed by clinical trials and by clinical 
experience, and the choice of drug depends on the safety profile 
Table 4. Synthetic DMARDs 
Indication Dose Side-effects Monitoring Contraindications





7.5 - 25 mg 
weekly orally or 
subcutaneously
Common: nausea and 
vomiting, mucositis, 
alopecia, elevated liver 
enzymes, anaemia, 
neutropenia
Baseline CXR; full 
blood count and liver 
transaminase test within 
the first month of 




liver disorders, renal 







folic acid 5 - 10 
mg/week, 24 hrs 
after MTX
Less frequent: pneumonitis, 
teratogenic
Caution in HIV-positive 
patients
CQ Mild RA or 




(generally 200 mg 3 








Less frequent: retinopathy 
and myopathy 
SSZ Monotherapy 
if MTX not 
tolerated or 
contraindicated, 
or as part of 
combination 
therapy
1 - 3 g/day, orally Common: gastrointestinal 
intolerance (anorexia, 
nausea, vomiting), skin 
rash, elevated liver 
enzymes, myelosuppression
Full blood count and liver 
transaminase test within 
the first 1 - 2 months of 
treatment, and thereafter 
3 - 6-monthly
Leflunomide Monotherapy or 
in combination 
with MTX
20 mg/day orally, 
but 20 mg on 
alternate days can 
be used
Nausea, vomiting, 
abdominal pain, diarrhoea, 
alopecia, elevated liver 
enzymes, skin rash 
Full blood count and 
liver transaminase test 
within the first month of 




is recommended 2 
years before a possible 
pregnancy; alternatively, 
cholestyramine washout.
Teratogenic in both male 
and female patients
DMARD = disease-modifying anti-rheumatic drug; MTX = methotrexate; CXR = chest X-ray; CQ = chloroquine; RA = rheumatoid arthritis; SSZ = sulphasalazine.
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and on the patient’s preferred route of administration. At present, 
the optimal sequence of biologics remains unclear. In future, 
biomarkers may assist in identifying the most appropriate biologic 
agent for an individual patient.[35] 
A biologic DMARD that has not resulted in an adequate clinical 
response after 6 months of treatment should be withdrawn and 
another biologic DMARD should be prescribed.[36]
5.5 Analgesics and anti-inflammatory drugs 
Analgesics should be prescribed and taken on an ‘as needed’ basis 
for pain control. Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are effective in controlling pain and stiffness, but are purely 
symptomatic therapies and offer no disease-modifying action. 
The toxicity of these drugs should not be underestimated. In RA, 
NSAIDs are often prescribed on a long-term basis, but should be 
used with caution as many patients have risk factors for NSAID-
induced gastrointestinal tract events. Particularly at risk are older 
patients (age >60 years), as well as those who are co-prescribed 
corticosteroids and aspirin. Hence, there should be a low threshold 
for co-prescribing a proton pump inhibitor for gastroprotection, or 
for considering a COX-2 selective agent (coxib).[37] In addition, all 
NSAIDs, both non-selective agents and coxibs, confer an increased 
risk of thrombotic events, and should be used with caution in 
patients with cardiovascular risk factors.[38] Other side-effects 
of NSAIDs, including hypertension, renal and liver dysfunction 
should not be forgotten. Blood pressure should be checked within 
a month of initiating NSAID therapy. Ideally, NSAIDs should be 
used in the lowest effective dose and for the shortest duration of 
time, and withdrawn if possible once disease activity is controlled 
with DMARDs.
5.6 Extra-articular disease
Moderate to high-dose GCs, possibly combined with other immuno-
suppressant drugs, are used in severe extra-articular disease including 
serositis, vasculitis and scleritis.
5.7 Multidisciplinary team
Care of the RA patient requires a multidisciplinary approach with 
referral to an occupational therapist, podiatrist, physiotherapist, clinical 
psychologist and social worker, as appropriate. A rheumatology nurse can 
offer patient education and support, with positive effects on adherence 
to therapy and on health-related quality of life.[39] Adoption of a healthy 
lifestyle that includes regular exercise, loss of weight if overweight, and 
discontinuation of smoking is of benefit. Smoking has been shown not 
only to increase the risk of developing RA, but also to worsen the severity 
of joint disease, extra-articular complications and comorbidities of RA.[40]
Referral of the RA patient for orthopaedic surgery may be appropriate 
in certain circumstances. Importantly, surgical treatment of RA is only 
an adjunct to medical control of the disease with DMARDs. With 
modern aggressive therapy of RA, the number of patients requiring 
joint replacements and other surgical interventions is declining.[41] 
6. Complications and safety issues
6.1 TB
All RA patients are at increased risk of TB, and this risk is increased 
by drugs used to treat RA including GCs, MTX and biologic drugs, in 
particular anti-TNF therapy.[42] The pro-inflammatory cytokine TNF 
plays an essential role in the containment of mycobacterial infection in 
granulomas, and inhibition of TNF may lead to reactivation of latent 
TB, or possibly to new TB infection.[43] This reactivation of TB generally 
occurs within the first 3 - 6 months of initiation of anti-TNF therapy. 
Table 5. Biologic DMARDs currently available in South Africa
Medication Target Type Route Dose
Half-life (days)
n Special comments
Anti-TNF Extensive data from clinical trials and 
clinical experience; hence used as 
first-line biologics in most countries. 
Dose adjustment possible. These drugs 
confer increased risk of TB.




IV 3 mg/kg every 8 
weeks
8 - 10
Etanercept TNF-α Soluble 
receptor fusion 
protein
S/C 50 mg weekly (or 25 
mg twice weekly)
4
Adalimumab TNF-α Human 
monoclonal 
antibody








IV Weight dependant 
500 mg, 750 mg or 
1 000 mg every 4 
weeks
8 - 25 Useful where high risk of sepsis. 
Useful in heart failure.
Rituximab CD20+ B cells Mouse/human 
chimeric 
antibody
IV 2 x 1 000 mg 14 days 
apart 6-monthly or 
at disease flare
19 - 22 Useful in seropositive patients. Long 
half-life, thus less flexibility if adverse 
effects or poor response.
Tocilizumab IL-6 receptor Humanised 
IL-6 receptor 
antibody 
IV 8 mg/kg every 8 
weeks
13 Useful for IL-6 driven disease 
anaemia, high CRP, fatigue.
DMARD = disease modifying anti-rheumatic drug; TNF = tumour necrosis factor; IV = intravenous; S/C = subcutaneous; IL = interleukin.
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The presentation may be atypical, with over half of cases reported as 
extra-pulmonary, and a high proportion of disseminated TB.[44]
Prior to initiation of therapy, each patient requires screening for latent 
TB infection (LTBI), and an assessment of the risk of TB infection/
reactivation (risk stratification).
6.1.1 Screening for LTBI
The efficacy of screening for and treatment of LTBI before initiation of 
anti-TNF therapy has been well demonstrated, but the most appropriate 
test to detect LTBI is uncertain.[44-46] In a high prevalence setting such as 
SA, there is no reliable test for LTBI. The tuberculin skin test (TST) has 
traditionally been the primary tool for identifying LTBI, but limitations 
include false-negative results in immunocompromised patients (for 
example patients on immunosuppressive drugs such as MTX or 
corticosteroids[47]) and a false-positive test after BCG vaccination at 
birth, although this is not believed to be very significant amongst 
adults.[48] Other problems with the TST are the logistics of return visits 
for evaluation, and variations in administration and interpretation 
of the test.[49] Despite this, detection of LTBI by TST (defined as 
induration ≥5  mm) is highly effective. Recently, interferon (IFN)-γ 
release assays (IGRAs), which measure IFN-γ response to TB-specific 
antigens, have been introduced. While excellent performance and good 
cost effectiveness of these tests have been reported,[50] a negative IGRA 
does not exclude LTBI. In low-prevalence settings, the combination 
of TST and IGRA may be the best strategy.[51] Currently, there is little 
consensus on the most appropriate screening test in high-prevalence 
settings such as SA.[52]
A patient due to commence biologic therapy should have a TST, 
an IGRA test (if deemed appropriate by the clinician), and a CXR. 
An abnormal CXR suggesting active pulmonary TB clearly needs 
investigation, and treatment for the patient. A patient with a positive 
TST, and a normal CXR, should be given anti-TB chemoprophylaxis. 
Extrapolating from studies in HIV-positive patients, chemoprophylaxis 
may be either isoniazid (INH) for 9 months, or rifampicin combined 
with INH for 3 months.[53] The consensus is that anti-TNF therapy can be 
initiated after completion of a minimum of 1 month of chemoprophylaxis.
6.1.2 TB risk stratification
The incidence of TB in SA is amongst the highest in the world, with an 
estimated incidence of 808 per 100 000 in the general population.[54] In 
light of this, there are valid concerns regarding the safety of anti-TNF 
drugs, and all patients must be considered to be at relatively high risk 
of TB. In the absence of prospective data, recommendations must err 
on the side of caution. 
The risk of developing active TB in RA patients treated with 
biologic DMARDs appears to depend on the background prevalence 
of LTBI. Factors associated with LTBI in the USA and in Hong Kong 
include older age, residence or travel in a TB-endemic area, high-risk 
occupation (healthcare or institution worker), previous TB infection, 
Felty’s syndrome, and low socio-economic status.[55,56] Concomitant 
corticosteroid use and monoclonal rather than soluble anti-TNF drugs 
seem to confer a higher risk for TB.[46,57,58] Non-anti-TNF therapy appears 
to confer a much lower risk of TB, but cases have been reported.[59]
6.1.3 Very high-risk patients
Patients who are stratified as being at very high risk of LTBI and who 
require biologic therapy need careful consideration. This stratification 
is left to the physician’s discretion, but would include healthcare 
workers, inmates or employees at institutions, patients who have had 
previous TB or who have a poor socio-economic background.
If such a high-risk patient is to commence anti-TNF therapy, a 
strategy offering 9 months of INH prophylaxis, regardless of TST/
IGRA result, may be appropriate. Such a policy has been adopted in 
India because of the high incidence of TB.[60] Despite concerns of INH 
toxicity and of propagating INH-resistant TB, this strategy may be 
valid in high-risk settings such as SA. Longer-term chemoprophylaxis, 
continued for the duration of anti-TNF therapy, may be appropriate in 
very high-risk patients, but there are no prospective data.
Alternatively, non-anti-TNF drugs may be the safest choice of first-
line biologic therapy in such patients. This is the current practice in 
Algeria and Morocco, and has been shown to be effective in high-risk 
patients in Germany.[61,62]
6.2 Other infections
There is an increased risk of infection amongst RA patients, particularly 
in patients treated with biologic therapy.[30] These include serious 
bacterial infections, as well as opportunistic fungal (histoplasmosis 
in particular), Listeria and non-tuberculous mycobacterial infections. 
Hence, biologic drugs should be used with caution in patients 
with chronic infected leg ulcers, septic arthritis in the preceding 
12 months, septic arthritis of prosthetic joints, recurrent urinary 
or respiratory tract infections, an indwelling urinary catheter, or 
hypogammaglobulinaemia.
In the presence of active infection, administration of a biologic 
drug should be delayed. MTX does not increase the risk of sepsis or 
peri-operative complications in patients undergoing joint replacement 
surgery, and can be continued.[63] There may be a small risk of peri-
operative infections in patients using biologic DMARDs, and it is 
recommended that these drugs are discontinued prior to surgery for a 
period of 3 - 5 times the half-life of the drug, and resumed after good 
wound healing. 
6.3 HIV infection 
In SA, the burden of HIV infection is amongst the highest in the 
world, with an estimated 33% of females between the ages of 25 
and 29 years infected in 2010.[64] This pandemic has both diagnostic 
and therapeutic implications for the management of patients with 
concomitant inflammatory arthritis.[65] 
HIV infection can cause, among other musculoskeletal syndromes, 
inflammatory polyarthritis mimicking RA.[66] Hence, an HIV test may be 
appropriate in a patient presenting with inflammatory arthritis.
There are several challenges in the management of RA patients 
who are HIV-positive. Information on the safety of using 
immunosuppressive drugs in an HIV-positive patient is limited. MTX 
and biologic drugs place patients at risk of opportunistic infections, 
and there is concern of added immunosuppression if prescribed in 
an HIV-positive patient.[67] For this reason, these therapies are not 
recommended and CQ (which may have antiviral properties[68]) 
or SSZ may be more appropriate choices. In addition, there are 
difficulties in the assessment of disease activity in HIV-positive 
patients due to the nonspecific increase in erythrocyte sedimentation 
rate (ESR) associated with HIV infection.[69] Little is known about the 
effect of antiretroviral therapy (ART) on RA disease, or the safety of 
biologic drugs in patients receiving ART. These are areas for future 
research.
6.4 Viral hepatitis
Hepatitis B reactivation can occur in hepatitis B surface antigen (HBsAg)-
positive patients treated with MTX or biologic therapy (particularly 
rituximab). Thus, screening for viral hepatitis before starting treatment 
in high-risk patients is recommended.[70] Hepatitis B vaccination should 
ideally be offered to non-immune patients before commencing DMARD 
treatment. In hepatitis C-infected patients, anti-TNF therapy and 
rituximab is considered safe, and possibly beneficial.[71]
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6.5 Vaccination
Patients with RA should receive killed vaccines based on age and risk, 
ideally at least 14 days before commencing DMARD or biologic therapy 
for optimal efficacy. These might include influenza, pneumococcal, 
hepatitis B and human papillomavirus vaccines. Live vaccines including 
herpes zoster and yellow fever vaccines are not recommended in RA 
patients on MTX or biologic therapy. It may, however, be appropriate to 
vaccinate a patient likely to travel to a high-risk yellow fever area, prior 
to commencing biologic therapy. 
6.6 Cardiovascular events 
Due to a combination of systemic inflammation and traditional 
cardiovascular risk factors, patients with RA have increased 
cardiovascular disease and risk of cardiovascular death, similar to that 
seen in patients with type 2 diabetes.[72] Traditional risk factors including 
smoking, hypertension, diabetes mellitus, and dyslipidaemia (most 
importantly low levels of high-density lipoprotein (HDL) cholesterol and 
resultant high total cholesterol to HDL ratio) need to be addressed. [73] 
In SA, treatment of dyslipidaemia is based on cardiovascular risk 
estimation using the Framingham Risk Score.[74] In the setting of RA that 
is seropositive, extra-articular or established (≥10 year disease duration), 
this percentage risk should be multiplied by 1.5.[73]
Uncontrolled severe joint inflammation, extra-articular disease, 
physical inactivity and corticosteroid use further contribute to the risk 
of cardiovascular events.[75] Improved disease control with therapy, 
such as MTX and anti-TNF therapy, has been shown to decrease 
cardiovascular risk in RA patients.[76,77]
6.7 Osteoporosis
Bone loss is an important consequence of long-standing RA, and 
patients may require co-therapy with osteoclast-inhibiting agents 
or osteoblast stimulators. The pathogenesis of osteoporosis in RA is 
multi-factorial and can be cumulative over time. In early disease, the 
predominant feature is localised, or juxta-articular, osteoporosis, which 
is a consequence of locally acting pro-inflammatory cytokines. It is 
not yet clear whether biologic DMARDs are capable of retarding or 
reversing bone loss in RA, but studies are under way to evaluate this. 
One recent study[78] failed to show a significant impact on bone density 
following anti-TNF therapy, but the sample size and duration may have 
meant that it was under-powered.
Generalised osteoporosis affecting the femur and lumbar spine 
is usually seen in long-standing RA, especially in post-menopausal 
women. The mechanism is likely to be due to a combination of 
immobilisation, age, menopause, GC therapy and inflammation due 
to RA. The dose of prednisone associated with bone loss is likely 
to be as low as 2.5 mg daily.[79] The ACR has recently published 
revised guidelines for the treatment of GC-induced osteoporosis, 
recommending that a lower threshold for intervention be used, since 
fractures in these patients may occur when the bone mineral density 
T-score is >-2.5 but <-1.0.[80] Calcium and vitamin D supplementations 
are recommended for routine use in all patients likely to receive GC 
therapy for longer than 6 months, irrespective of dose. Control of joint 
inflammation with DMARD therapy will help to maintain the bone 
density by improving physical activity. 
6.8 Malignancy
Patients with RA are at increased risk of lymphoma, with the major risk 
being uncontrolled joint inflammation rather than DMARD therapy.[81] 
Neither synthetic nor biologic DMARDs seem to confer an increased 
risk of malignancy,[82,83] nor do they increase the chance of recurrence 
of a malignancy, or change the prognosis of cancers that occur in 
patients using biologic therapies.[84] The current recommendations are 
that biologic therapy be avoided in patients with a current or recent 
(<5 years) diagnosis of a malignancy. 
6.9 Pregnancy
RA tends to improve during pregnancy. In general, because of potential 
risks to the fetus, DMARDs are not recommended, and low-dose GCs 
may be adequate to control symptoms. MTX and leflunomide are 
contraindicated in pregnancy and breastfeeding, but SSZ and CQ are 
considered relatively safe and may be useful in active disease. There 
is sparse evidence for the safety of biologic drugs in pregnancy or 
lactation and formal recommendations are that anti-TNF drugs and 
rituximab be stopped 3 months and 12 months, respectively, before 
conception. However, there are recent reports of successful pregnancies 
in patients using anti-TNF drugs, and many experts feel that these 
drugs can be safely continued during conception and the first 2 
trimesters of pregnancy.[85] 
7. Monitoring patients on therapy 
Disease activity should be evaluated with an SDAI, and an intensive 
disease control strategy should be used with escalation of therapy if LDA 
or, ideally, remission is not achieved. Patients with moderate or high 
disease activity should be assessed frequently (1 - 3-monthly) until an 
LDA state is achieved, after which less frequent visits (3 - 6-monthly) 
are acceptable.
Monitoring for toxicity of DMARD therapy is summarised in 
Table 4. There is no indication for ‘routine’ liver biopsy in patients on 
MTX therapy. A biopsy may be indicated in a patient with persistently 
elevated liver enzymes (>3 times the upper level of normal) after 
DMARD discontinuation.[86] Annual serum creatinine and cholesterol 
tests are appropriate. Baseline bone mineral density measurements 
are recommended in post-menopausal women starting long-term GC 
therapy and should be repeated at 5-yearly intervals.
Because of the high risk of infection, including TB, RA patients 
and their physicians must remain vigilant for symptoms of infection. 
Patients should be advised to seek medical attention for any symptoms 
of possible infection, to allow for prompt assessment and treatment. 
Loss of weight, fever or lymphadenopathy in a patient on biologic 
therapy requires prompt investigation for TB, which might include a 
CXR, abdominal ultrasound and bone marrow aspiration.
8. SA rheumatologist survey 
An online survey was sent to all SA rheumatologists to assess the level of 
agreement with 9 statements on management of RA. Rheumatologists 
were asked to score their agreement with each statement on a 10-point 
numerical scale (10 = agree completely; 0 = do not agree at all). The 
response rate to the survey was 46/81 (57%), and results are shown in 
Table 6. Importantly, there was strong support for an intensive control 
strategy involving frequent (1 - 3-monthly) visits, and calculation of a 
composite disease activity index with escalation of therapy if LDA is 
not achieved. In addition, there was excellent agreement regarding the 
selection of patients for biologic therapy. Of interest, the vast majority 
(83%) of SA rheumatologists concur that in patients at high risk of 
TB, non-TNF biologic therapy may be the more appropriate first-line 
therapy. There was moderate agreement (64%) with an approach giving 
INH prophylaxis to all high-risk patients starting anti-TNF treatment. 
9. Economic aspects of therapy 
The costs of therapy to treat RA, which may include the considerable 
expense of biologic drugs in patients who do not respond to synthetic 
DMARDs alone, need to be balanced against the consequences of 
uncontrolled disease with ensuing joint damage and disability. Loss of 
productivity in the home and workplace, loss of income, isolation from 
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society and reduced recreational comforts, together with the negative 
psychosocial impact of the disease, have severe economic consequences 
for patients, their families, and to society.[87] The measures used to 
quantify these effects include the disability adjusted life-years (DALY) 
and the quality of life-years lost (QALY). 
The costs of therapy will be relatively low in patients receiving non-
biologic DMARDs, but will escalate when biologic DMARDs are added. 
When comparing different therapies for the treatment of RA, the number 
needed to treat (NNT) to achieve a response may be a useful reference. 
Such calculations will differ, depending on the tool used to measure 
response. Most studies base their calculations on achieving an ACR 50 
response in a 70 kg subject. A recent meta-analysis of the cost-effectiveness 
of all biologics showed that the NNT varied between 2.8 and 5.7.[88]
A recent systematic review of the literature, which contributed to 
the EULAR recommendations, showed that the merits of effective 
control of RA outweigh the costs of therapy.[89] At disease onset, 
synthetic DMARDs should be initiated. If these fail, treatment 
escalations with biologic therapy are cost-effective, provided standard 
dosing schemes are used. 
10. Areas for future research 
There are several areas for future research to provide answers to 
optimal RA management in our unique SA situation. The most 
important issues revolve around TB, including the safety of biologic 
DMARDs, and the risk factors for development of TB. Contemporary 
epidemiological data on the prevalence and incidence of RA in SA are 
needed. Other areas for investigation include management of RA in 
HIV-positive patients, the burden of RA on productivity in SA, and 
local exploration of the cost-effectiveness of RA treatment. 
Due to recent advances in RA therapies, it is suggested that these 
recommendations are updated every 2 years.
In summary, effective management of RA requires prompt diagnosis, 
early initiation of DMARD therapy, and an intensive control strategy with 
frequent assessments and rapid escalation of therapy. The aim should be 
to achieve LDA or ideally remission. Biologic drugs should be considered 
in patients who have shown inadequate response to synthetic DMARDs.
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